PEL

Piramal Healthcare Limited has informed the Exchange regarding a press release dated July 02, 2008, titled "Piramal Healthcare Acquires Haemaccel Brands Group of PlasmaSelect AG, Germany". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/piramalhealth_PR_02072008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated May 13, 2008, titled "Piramal Life Sciences initiates Phase I trials with a new molecule for Type II Diabetes in Europe". Further the Company has informed the Exchange that "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to Piramal Life Sciences Limited (PLSL) pursuant to the Composite Scheme of Arrangement which has been sanctioned by the Hon'ble Bombay High Court. PLSL has already allotted its shares to the shareholders of the Company under the Scheme. The sha

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated April 30, 2008, titled "Nicholas Piramal signs Product Development & Licensing Agreement with DxTech for point-of-care diagnostic testing system". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_30042008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated April 24, 2008, titled "Nicholas Piramal reports Q4 & FY2008 results; Consolidated Revenues up for the Quarter by 19% to Rs. 7.7 billion, Operating Profit up by 140% to Rs. 2.0 billion, Net Profit up by 142% to Rs. 1.3 billion; Revenues for FY2008 up by 16% to Rs. 28.7 billion, Operating Profit for the year crosses Rs. 5 billion, Net Profit up by 53% to Rs. 3.3 billion making FY2008 a landmark year for the Company". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) un

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated April 15, 2008, titled "Nicholas Piramal India Limited acquires Anafortan and CEFI Brand Groups from Khandelwal Laboratories Pvt. Ltd.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_15042008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated March 11, 2008, titled "Piramal Group announces launch of new corporate identity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NICHOLAS_PR_11032008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange vide its letter dated February 26, 2008 that "NPIL Research and Development Limited ("NRDL") (name now changed to Piramal Life Sciences Limited) has commenced Phase I studies of a new experimental drug molecule, P1201-07, in The Netherlands." The Company has further informed the Exchange that: "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to NRDL pursuant to the Composite Scheme of Arrangement which has been sanctioned by the Hon'ble Bombay High Court. The Record Date for issue of shares by

Nicholas Piramal India Ltd. has informed the Exchange vide its letter dated February 22, 2008, that: "NPIL Research & Development Limited ('NRDL') has signed an Agreement with the Department of Biotechnology, New Delhi on 'Screening for Bio-molecules from Microbial Diversity Collected from Different Ecological Niches', thereby initiating an industry - university / national institute partnership programme in drug discovery". The Company has further informed the Exchange that: "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to NRDL pursuant to the

Nicholas Piramal India Ltd. has informed the Exchange that NPIL Research & Development Limited ('NRDL'), has signed a second new drug development agreement with Eli Lilly and Company ('Eli Lilly') to develop and in certain regions, commercialise, a select group of Eli Lilly's pre- clinical drug candidates that span multiple therapeutic areas. Further the Company has informed the Exchange that "It may be recalled that the Company (i.e. Nicholas Piramal) has demerged its NCE Research Unit to NRDL pursuant to the Composite Scheme of Arrangement which has been sanctioned by the Hon'ble Bombay High

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 25, 2008, titled "Nicholas Piramal and Pierre Fabre Laboratories sign agreement on research in oncology in the presence of French President Nicolas Sarkozy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_25012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 22, 2008, titled "Nicholas Piramal India Limited buys Pharmaceuticals business of Healthline Private Limited, Bangalore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_22012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 18, 2008, titled "Nicholas Piramal reports Q3 FY2008 results; Total Revenues grow 13% to Rs. 7.3 billion, Net Profit up by 31% to Rs. 727.6 million; Domestic formulations Sales grow by 15.6% to Rs. 3.4 billion". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPir_PR_18012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 15, 2008, titled "Dr L H Hiranandani Hospital outsources its Radiology Department to Nicholas Piramal India Limited Subsidiary Wellspring". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPiramal_PR_15012008.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated December 19, 2007, titled "Nicholas Piramal enters into a Joint Venture with ARKRAY, Inc. Japan, for marketing Diagnostic products, mainly Self-Monitoring Blood Glucose System in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_19122007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated December 10, 2007, titled "Nicholas Piramal secures Product Patent from US Patent & Trademark Office for its Cyclin-Dependent Kinase (CDK) Inhibitors; Dr. Noopur Raje from Dana Faber Cancer Institute presenting on NPIL's lead compound P-276-00 at 49th American Society of Hematology Conference at Atlanta, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated November 19, 2007, titled "Nicholas Piramal Announces Drug Discovery and Development Agreement with Merck & Co., Inc.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_19112007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated October 25, 2007, titled "Nicholas Piramal reports Q2 FY2008 results; Total Revenues grow 17% to Rs.7.6 billion, Net Profit up by 58% to Rs.847.4 million". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_25102007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated July 25, 2007, titled "Nicholas Piramal reports Q1 FY2008 results; Total Revenues increased 16.4% to Rs.6.1 billion, Net Profit was lower by 19.4% to Rs.434.3 million". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPiramal.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated July 23, 2007, titled "Nicholas Piramal India Limited's IND-P276- a new drug discovery from Mumbai, India has been approved by USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_23072007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release, dated April 26, 2007, titled "Nicholas Piramal reports Q4 FY2007 results; Consolidated Revenues up 51.7% to Rs. 6.4 billion, Operating Profit up 137.9% to Rs. 848.9 million, Net Profit up 262.2% to Rs 549.5 million." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release that was issued by the Custom Manufacturing Business Division [NPIL Pharma] at the Informex USA Specialities / Pharma Services Trade Show in San Francisco, USA last night. The Press Release provides details regarding certain development in formulation capabilities and growth plans of NPIL Pharma. The press release dated February 14, 2007, titled "Formulation capabilities to leverage NPIL Pharma growth" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release, dated January 22, 2007, titled "Napo Enters Plant Screening Agreement with Nicholas Piramal India Limited for Diabetes ." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPir_PR_22012007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 18,2007, titled "Nicholas Piramal reports Q3 FY 2007 results; Consolidated Revenues up by 60.1% to Rs. 6.5 billion, Operating Profit up by 185.3% to Rs. 970.4 million, Net Profit up by 473.9% to Rs. 555.5 million". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPir_PR_18012007.zip target=NEW> For more details click

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated January 12, 2007 titled "Nicholas Piramal announces Drug Development Agreement with Eli and Company - Collaboration Represents a New Clinical Development Model". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nichopir_PR_12012007.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange that "Wellspring, the chain of Pathology Laboratories and Diagnostic Centres promoted by Nicholas Piramal India Ltd (NPIL), has acquired Jankharia Imaging, the most successful radiology and imaging centre in Mumbai. The new entity would be renamed as Wellspring Jankharia Imaging. The acquisition has been done by NPIL's wholly-owned subsidiary NPIL Laboratories & Diagnostics Pvt. Ltd. The Company also submitted a copy of press release dated January 04, 2007, titled �Nicholas Piramal's Wellspring acquires majority stake in Jankharia Imaging t

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated November 17,2006, titled "BioSyntech signs scientific collaboration agreement with Nicholas Piramal". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasP_PR_17112006.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated October 27,2006, titled "Nicholas Piramal signs two Platform Technology agreements with Morvus Technology Limited, UK, for R&D programs in Diabetes, Rheumatoid Arthritis and Oncology". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/NicholasPir_PR_27102006.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated October 16,2006, titled "Nicholas Piramal reports Q2 FY2007 results; Consolidated Revenues up by 79.3% to Rs.6.5 billion, Operating Profit up by 76.7% to Rs.1.1 billion, Net Profit up by 17.7% to Rs.536.9 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_181006.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated September 29, 2006, titled "Nicholas Piramal announces acquisition of balance 51% equity stake in Boots Piramal Healthcare Private Limited", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Nicholas_PR_03102006.zip target=NEW> For more details click here.</a>

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated August 30,2006, titled "Nicholas Piramal's Wellspring acquires 100 pc stake in Dr Phadke's path labs". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Nicholas Piramal India Ltd. has informed the Exchange regarding a Press Release being issued by the Company in connection with the acquisition of the manufacturing facility of Pfizer Inc. located at Morpeth, Northumberland, UK. The site is one of Pfizer's global, high quality, integrated facilities and has end-to end production and supply chain capabilities that cover Active Pharmaceutical Ingredients (API), finished dosage, packaging and distribution. The transaction includes a supply agreement up till November 2011, totaling potential revenues exceeding US $ 350 million. This acquisition is

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated May 16,2006, titled "Nicholas Piramal India Limited contemplating acquisitions". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release being issued by the Company in connection with the signing of a long term Contract manufacturing related R & D Services Agreement with Pfizer International LLC as follows: "Nicholas Piramal India Limited, India today announced the signing of a long-term contract manufacturing related R&D Services Agreement with Pfizer International LLC. The agreement is for a period of seven years, and is renewable thereafter. Under this agreement, NPIL will provide Process Development and Scale-up services to Pfizer's Animal Hea

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release dated November 24, 2005, issued by the Company in connection with the signing of a long-term Manufacturing and Supply Agreement with a large global hospital products company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release being issued by the Company in connection with the acquisition of Avecia Pharmaceuticals Ltd (U.K) and its group company Torcan Chemical Ltd (Canada). The details of the press release dated October 27,2005 titled, "Nicholas Piramal acquires Avecia Pharmaceuticals, UK for a consideration of GBP 9.5 million", shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. has informed the Exchange regarding a press release being issued by the Company in connection with the development and know-how agreement signed with AstraZeneca. A press release with regards to the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. had informed the Exchange regarding the proposal for investment of Can$ 6 million in the share capital of BioSyntech, Canada, subject to requisite RBI approvals. The Company has now informed that the private placement of 7,500,000 common shares at a price of Canadian $0.80 per share aggregating to Can$ 6 million in BioSyntech, Canada has been completed. The details of the press release issued in this regard shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncemen

Nicholas Piramal India Ltd. has informed the Exchange regarding a Press Release, dated, July 29, 2005, titled "Nicholas Piramal Q1FY06 Net Sales up 8.8%; PAT up 11.1%- Domestic Formulations grow 14.1%, Exports up 49.3%. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. has informed the Exchange regarding a Press Release, dated, July 14, 2005, titled "Nicholas Piramal announces commencement of Phase I/II clinical studies on oncology lead research molecule P276-00.". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. has submitted to the Exchange a copy of the press release being issued by the Company, relating to investment of Can$ 6 million in the equity shares of Biosyntech Inc., which has been approved at the Board Meeting held on July 07, 2005, subject to requisite RBI approvals. Biosyntech is a Canada-based biotechnology research company that specializes in the discovery, development and manufacture of innovative, cost-effective biologic implants for regenerative medicine and therapeutic delivery. A copy of the press release shall be available on the NSE website (http://ww

Nicholas Piramal India Ltd. has informed the Exchange that the company has submitted IND to Canadian regulators for Phase-1 clinical trials for its oncology lead molecule P-276-00. The details of the press release issued by the Company regarding the Audited Results for the FY ended March 31, 2005 and the commencement of clinical trials aforesaid shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. has informed the Exchange that the company has issued a press release dated January 21, 2005 titled 'Nicholas Piramal reports Q3-FY05 results; Sales from continuing operations up 13.8%, profit after tax up 118.2%'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. has informed the Exchange that the company has secured Custom Manufacturing Agreements with two leading international companies. The first is for manufacture and supply of various pharmaceutical products to a leading pharmaceuticals company ranking among the top Fortune 500 companies in the world, for sale in the US market. The second Agreement is with Allergan, Inc., USA for the manufacture of two high-value, Anti-Glucoma APIs (Active Pharmaceutical Ingredients). NPIL will cater to Allergan's worldwide requirements of Levobunolol (used in Betagan formulations) and

Nicholas Piramal India Ltd. has informed the Exchange that there has been a fire at Centre Point Building, Parel, Mumbai, on October 29, 2004 at 4.00 am, which houses one of the office premises of the Company. There has been no casualty. The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).